Intracellular target delivery of cell-penetrating peptide-conjugated dodecaborate for boron neutron capture therapy (BNCT)

2019 ◽  
Vol 55 (93) ◽  
pp. 13955-13958 ◽  
Author(s):  
Ikuhiko Nakase ◽  
Miku Katayama ◽  
Yoshihide Hattori ◽  
Miki Ishimura ◽  
Shunsuke Inaura ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Cell Penetrating Peptides ◽  
Cell Penetrating Peptide ◽  
Neutron Capture Therapy ◽  
Boron Compounds ◽  
Target Delivery ◽  
Boron Neutron Capture ◽  
Cell Penetrating ◽  
Intracellular Target

Boron neutron capture therapy (BNCT) technology using cell-penetrating peptides (CPPs) for enhanced cellular uptake of boron compounds and their controlled localization inside cells.

The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide

Biomaterials ◽  
2014 ◽  
Vol 35 (10) ◽  
pp. 3396-3405 ◽  
Author(s):  
Hiroyuki Michiue ◽  
Yoshinori Sakurai ◽  
Natsuko Kondo ◽  
Mizuki Kitamatsu ◽  
Feng Bin ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Cell Penetrating Peptide ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Cell Penetrating

Intracellular distribution of various boron compounds for use in boron neutron capture therapy

1993 ◽  
Vol 45 (1) ◽  
pp. 147-155 ◽  
Author(s):  
Nguyen Tien ◽  
Gordon L. Brownell ◽  
Sylvia A. Holden ◽  
Beverly A. Teicher
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Intracellular Distribution ◽  
Neutron Capture Therapy ◽  
Boron Compounds ◽  
Boron Neutron Capture

Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model

2010 ◽  
Vol 50 (1) ◽  
pp. 199-207 ◽  
Author(s):  
Marcela A. Garabalino ◽  
Andrea Monti Hughes ◽  
Ana J. Molinari ◽  
Elisa M. Heber ◽  
Emiliano C. C. Pozzi ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Experimental Model ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Compounds ◽  
Boron Neutron Capture ◽  
Biodistribution Studies

Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages

2005 ◽  
Vol 103 (6) ◽  
pp. 1000-1009 ◽  
Author(s):  
Shin-Ichi Miyatake ◽  
Shinji Kawabata ◽  
Yoshinaga Kajimoto ◽  
Atsushi Aoki ◽  
Kunio Yokoyama ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Tumor Volume ◽  
Malignant Gliomas ◽  
Neutron Capture Therapy ◽  
Boron Compounds ◽  
Content Type ◽  
Boron Neutron Capture ◽  
Fine Print

Object. To improve the effectiveness of boron neutron capture therapy (BNCT) for malignant gliomas, the authors used epithermal rather than thermal neutrons for deep penetration and two boron compounds—sodium borocaptate (BSH) and boronophenylalanine (BPA)—with different accumulation mechanisms to increase the boron level in tumors while compensating for each other's faults. Methods. Thirteen patients, 10 of whom harbored a glioblastoma multiforme (GBM), one a gliosarcoma, one an anaplastic astrocytoma, and one an anaplastic oligoastrocytoma, were treated using this modified BNCT between January 2002 and December 2003. Postoperatively, neuroimaging revealed that only one patient with a GBM had no lesion enhancement postoperatively. The patients underwent 18F-BPA positron emission tomography, if available, to assess the accumulation and distribution of BPA before neutron radiotherapy. The neutron fluence rate was estimated using the Simulation Environments for Radiotherapy Applications dose-planning system before irradiation. The patients' volume assessments were performed using magnetic resonance (MR) imaging or computerized tomography (CT) scanning. Improvements in the disease as seen on neuroimages were assessed between 2 and 7 days after irradiation to determine the initial effects of BNCT; its maximal effects were also analyzed on serial neuroimages. The mean tumor volume before BNCT was 42.3 cm3. Regardless of the pre-BNCT tumor volume, in every patient harboring an assessable lesion, improvements on MR or CT images were recognized both at the initial assessment (range of volume reduction rate 17.4–71%, mean rate 46.4%) and at follow-up assessments (range of volume reduction rates 30.3–87.6%, mean rate 58.5%). More than 50% of the contrast-enhanced lesions disappeared in eight of the 12 patients during the follow-up period. Conclusions. This modified BNCT produced a good improvement in malignant gliomas, as seen on neuroimages.

1H and 10B NMR and MRI investigation of boron- and gadolinium–boron compounds in boron neutron capture therapy

2011 ◽  
Vol 69 (12) ◽  
pp. 1702-1705 ◽  
Author(s):  
M. Bonora ◽  
M. Corti ◽  
F. Borsa ◽  
S. Bortolussi ◽  
N. Protti ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Compounds ◽  
Boron Neutron Capture
Sign in / Sign up

Export Citation Format

Share Document